Dihydropyridine Calcium Channel Blockers and the Risk of Severe COVID-19

被引：13
|
作者：
Mendez, Sean R. [1 ]
Frank, Rachel C. [2 ]
Stevenson, Elizabeth K. [5 ]
Chung, Mabel [3 ,4 ,6 ]
Silverman, Michael G. [2 ,4 ]
机构：
[1] Massachusetts Gen Hosp, Dept Med, Boston, MA USA
[2] Massachusetts Gen Hosp, Div Cardiol, Dept Med, Boston, MA USA
[3] Massachusetts Gen Hosp, Crit Care & Pain Med, Dept Anesthesia, Boston, MA USA
[4] Massachusetts Gen Hosp, Heart Ctr Intens Care Unit, Boston, MA USA
[5] North Shore Med Ctr, Crit Care, Div Pulm, Salem, MA USA
[6] Smith Ctr Outcomes Res Cardiol, Div Cardiovascular Med, Dept Med, Beth Israel Deaconess Med Center, Boston, MA USA
来源：
CHEST | 2021年 / 160卷 / 01期
基金：
美国国家卫生研究院;
关键词：
D O I：
10.1016/j.chest.2021.01.073
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
[No abstract available]
引用
收藏
页码：89 / 93
页数：5
相关论文
共 50 条
  • [41] Risk Factors for Severe COVID-19 in Children
    Graff, Kelly
    Smith, Christiana
    Silveira, Lori
    Jung, Sarah
    Curran-Hays, Shane
    Jarjour, Jane
    Carpenter, Lauren
    Pickard, Kasey
    Mattiucci, Michael
    Fresia, JoEllen
    McFarland, Elizabeth J.
    Dominguez, Samuel R.
    Abuogi, Lisa
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2021, 40 (04) : E137 - E145
  • [42] Genetic risk factors for severe COVID-19
    Bottcher, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 31 - 31
  • [43] Impact of Workplace on the Risk of Severe COVID-19
    Nakamura, Tsuyoshi
    Mori, Hiroyuki
    Saunders, Todd
    Chishaki, Hiroaki
    Nose, Yoshiaki
    FRONTIERS IN PUBLIC HEALTH, 2022, 9
  • [44] Risk Factors for Severe COVID-19 in Children
    Woodruff, Rebecca C.
    Campbell, Angela P.
    Taylor, Christopher A.
    Chai, Shua J.
    Kawasaki, Breanna
    Meek, James
    Anderson, Evan J.
    Weigel, Andy
    Monroe, Maya L.
    Reeg, Libby
    Bye, Erica
    Sosin, Daniel M.
    Muse, Alison
    Bennett, Nancy M.
    Billing, Laurie M.
    Sutton, Melissa
    Talbot, H. Keipp
    McCaffrey, Keegan
    Pham, Huong
    Patel, Kadam
    Whitaker, Michael
    McMorrow, Meredith L.
    Havers, Fiona P.
    PEDIATRICS, 2022, 149 (01)
  • [45] Hypozincemia in the early stage of COVID-19 is associated with an increased risk of severe COVID-19
    Fromonot, Julien
    Gette, Mickael
    Ben Lassoued, Amin
    Gueant, Jean-Louis
    Gueant-Rodriguez, Rosa-Maria
    Guieu, Regis
    CLINICAL NUTRITION, 2022, 41 (12) : 3115 - 3119
  • [46] Dihydropyridine calcium channel blockers may increase mortality in patients with heart failure
    Howlett, JG
    Johnstone, DE
    Cox, JL
    CIRCULATION, 2003, 108 (17) : 341 - 341
  • [47] Angioedema associated with dihydropyridine calcium-channel blockers in a child with Burkitt lymphoma
    Pierce, Wesly A.
    Hederman, April D.
    Gordon, Catherine J.
    Ostrenga, Andrew R.
    Herrington, Betty
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2011, 68 (05) : 402 - 406
  • [48] A cautionary note for nephrologists: Is it time to abandon the use of dihydropyridine calcium channel blockers?
    Jafar, TH
    Pereira, BJG
    SEMINARS IN DIALYSIS, 1999, 12 (03) : 137 - 139
  • [49] Safety of long-acting dihydropyridine calcium channel blockers in hypertensive patients
    Kloner, RA
    Vetrovec, GW
    Materson, BJ
    Levenstein, M
    AMERICAN JOURNAL OF CARDIOLOGY, 1998, 81 (02): : 163 - 169
  • [50] DO DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS INCREASE THE RISK OF NEUROMUSCULAR COMPLICATIONS IN PATIENTS WITH SARS-COV-2?
    Ahmed, Mohsen
    Ors, Muhammed
    Jaffry, Mustafa
    Trivedi, Ronak
    Souayah, Nizar
    MUSCLE & NERVE, 2022, 66 : S13 - S13
12345